Ralph Brindis, a former president of the ACC, explained that as physicians became familiar with TAVR they grew interested in exploring off-label uses of the device.
The NCD itself was originally proposed by the ACC and STS in response to concerns over the potential problems and confusion that a disruptive new technology like TAVR could unleash.
In a startling break with tradition, the American College of Cardiology and the Society of Thoracic Surgeons will manage and run their own clinical trials testing expanded uses for transcatheter aortic valve replacement (TAVR).
In the trial, patients not eligible for aortic valve surgery will receive TAVR through transapical and transaortic approaches and will be compared with the results of patients in the original PARTNER A trial who received TAVR through the transapical approach.
Following the approval of the first device for transcathether aortic valve replacement therapy (TAVR) earlier this month, the Society of Thoracic Surgeons (STS) and The American College of Cardiology (ACC) have announced the launch of th e TVT Registry, a joint initiative that will monitor the rollout of the new technology.